Marek’s Disease is a herpes virus infection commonly caused in chickens. The disease is characterized by a respiratory route of infection causing tumors on eyes, skin, nerves, and internal organs of chicken. Marek’s disease is highly contagious and readily transmitted among chickens. The not vaccinated household flocks are mostly affected by Marek’s disease. The common symptoms of this disease include the appearance of greyish-white tumors on internal organs, paralysis, weight loss, and vision impairment. The affected birds are highly susceptible to parasitic and bacterial infections. No specific treatment of Marek’s disease assures100% mortality among the chicken flocks.
Vaccination is a key control strategy for the prevention of Marek’s disease. The disease can be prevented by vaccination of embryo. A combination of vaccine types is used to achieve efficient cure. For instance, a trivalent vaccine program commonly HVT + SB1 + Rispen are effective in preventing losses due to Marek disease. Also, the increasing frequency of B21 gene through genetic engineering offers increased resistance to Marek’s disease.
Rising concerns of Marek disease in poultry-dense regions drive the global market
Poultry meat is currently the second largest (34%) meat market after pork. According to the study by Global Poultry Trends in 2014, an estimated 72% of increased consumption will be contributed by poultry. The factors driving the Marek’s disease market include rising disease outbreaks in poultry, growing demand for poultry-derived food products, high-intensity breeding, increased global shipping of poultry, and increasing prevalence of zoonotic diseases. Rising virulence of Marek’s Disease Virus such as serotype 2 virus, SB-1 virus, identification of disease resistant genes in chicken genome, and using microarray-based technologies for identification of resistant traits drives the global Marek disease market. The increasing consumer concern over food safety, demand for animal protein, increasing foodborne diseases, and greater livestock production rates are factors driving the demand for marek disease therapeutics market.
The global marek disease market is segmented on the basis of treatment, vaccines, and diagnosis.
On the basis of treatment, the global marek disease market is segmented into:
On the basis of vaccines, the global marek disease market is segmented into:
On the basis of diagnosis, the global marek disease market is segmented into:
High-Intensity production facilities of vaccines in North America drives the global marek disease market
Regional segmentation of the global marek disease market by Coherent Market Insights comprises North America, Latin America, Asia-Pacific, Europe, and the Middle East and Africa. North America is expected to dominate the global marek market, owing to high-intensity production facilities, innovative research, and development to provide genetic resistance through vaccines and biosecurity programs, growing virulence of the herpes virus, and identification of disease-resistance genes. Asia Pacific is expected to fuel the global market, owing to growing demand for poultry-derived food products, large livestock population, and increasing animal health awareness. Additionally, the diagnostic monitoring of virulent marek disease on a regular basis in Europe is further driving the overall growth of the market.
Higher efficiency offered by recombinant vaccines fuels manufacturer production
Manufacturers are investing in research and development to find the treatment for marek disease Key players operating the global marek disease market include Pfizer Inc, Sanofi-Aventis U.S., Merck & Co., Inc., Virbac, and Bayer Healthcare. For instance, cell-associated vaccines like CVI988/Rispens are highly effective for Marek’s disease, thus marking a drastic disease reduction in broiler and layer flocks.